Predictive Value of ERCC1 and XPD Polymorphism in Patients with Advanced Non-small Cell Lung Cancer Receiving Platinum-based Chemotherapy: a Systematic Review and Meta-analysis

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2010 Feb 10

PMID 20143185

Citations 34

Authors

Shu-Zhen Wei

Ping Zhan

Mei-Qi Shi

Yi Shi

Qian Qian

Li-Ke Yu

Yong Song

Affiliations

Soon will be listed here.

Abstract

The published data on the predictive value of polymorphism of ERCC1 and XPD in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Relevant studies were identified by searching the Medline, Embase, CNKI and American Society of Clinical Oncology abstract databases. Inclusion criteria were patients with advanced NSCLC, received platinum-based chemotherapy, evaluation of polymorphism of ERCC1 and XPD and overall response rate (ORR). A total of 12 studies were included in this meta-analysis. For studies evaluating ERCC1 polymorphism at codon 118, the ORR for the wild-type C/C genotype versus the heterozygous C/T and T/T genotype was 2.17 (95% confidence interval (CI), 1.43-3.33; P = 0.000). For studies evaluating XPD Asp312Asn and XPD Lys751Gln, the pooled OR was 1.33 (95% CI, 0.92-1.91; P = 0.13) and 1.02 (95% CI, 0.72-1.45; P = 0.915), respectively. The results indicated that platinum-based chemotherapy sensitivity was significantly associated with polymorphism of ERCC1 C118T. However, XPD Asp312Asn and XPD Lys751Gln were not predictive makers for platinum-based chemotherapy in patients with advanced NSCLC.

Citing Articles

Exploring Genetic Variants and Platinum Chemotherapy Response in Indonesian Non-Small Cell Lung Cancer Patients: Insights from rs13181.

Afifah N, Permatasari L, Diantini A, Intania R, Wijaya I, Obinata H Onco Targets Ther. 2024; 17:767-776.

PMID: 39319218 PMC: 11421434. DOI: 10.2147/OTT.S475219.

Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer.

Sito H, Tan S Mol Biol Rep. 2024; 51(1):102.

PMID: 38217759 DOI: 10.1007/s11033-023-08915-2.

Identifying polymorphic cis-regulatory variants as risk markers for lung carcinogenesis and chemotherapy responses in tobacco smokers from eastern India.

Sengupta D, Mukhopadhyay P, Banerjee S, Ganguly K, Mascharak P, Mukherjee N Sci Rep. 2023; 13(1):4019.

PMID: 36899086 PMC: 10006236. DOI: 10.1038/s41598-023-30962-9.

Genetic Polymorphisms in ERCC1 Gene and Their Association with Response to Radiotherapy in Moroccan Patients with Nasopharyngeal Carcinoma.

Benzeid R, Gihbid A, Tawfiq N, Benchakroun N, Bendahhou K, Benider A Asian Pac J Cancer Prev. 2023; 24(1):93-99.

PMID: 36708557 PMC: 10152845. DOI: 10.31557/APJCP.2023.24.1.93.

Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients.

Grenda A, Blach J, Szczyrek M, Krawczyk P, Nicos M, Kuznar Kaminska B Cancer Med. 2019; 9(2):605-614.

PMID: 31797573 PMC: 6970032. DOI: 10.1002/cam4.2743.

References

Furuta T, Ueda T, Aune G, Sarasin A, Kraemer K, Pommier Y . Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 2002; 62(17):4899-902. View

Camps C, Sarries C, Roig B, Sanchez J, Queralt C, Sancho E . Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin Lung Cancer. 2003; 4(4):237-41. DOI: 10.3816/clc.2003.n.004. View

Booton R, Ward T, Heighway J, Taylor P, Power F, Ashcroft L . Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer. 2006; 106(11):2421-7. DOI: 10.1002/cncr.21885. View

Wei Q, Frazier M, Levin B . DNA repair: a double-edged sword. J Natl Cancer Inst. 2000; 92(6):440-1. DOI: 10.1093/jnci/92.6.440. View

Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M . Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol. 2004; 15(8):1194-203. DOI: 10.1093/annonc/mdh319. View

Reed E . Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 1998; 24(5):331-44. DOI: 10.1016/s0305-7372(98)90056-1. View

Yu J, Mu C, Lee K, Okamoto A, Reed E, Mitchell K . A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res. 1997; 382(1-2):13-20. DOI: 10.1016/s1383-5726(97)00004-6. View

Potti A, Dressman H, Bild A, Riedel R, Chan G, Sayer R . Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006; 12(11):1294-300. DOI: 10.1038/nm1491. View

Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan A, Nannizzi S . Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2008; 14(6):1797-803. DOI: 10.1158/1078-0432.CCR-07-1364. View

10.

Su D, Ma S, Liu P, Jiang Z, Lv W, Zhang Y . Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer. 2007; 56(2):281-8. DOI: 10.1016/j.lungcan.2006.12.002. View

11.

Goode E, Ulrich C, Potter J . Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002; 11(12):1513-30. View

12.

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

13.

Gandara D, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M . Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009; 27(21):3540-6. PMC: 2717760. DOI: 10.1200/JCO.2008.20.8793. View

14.

Rosell R, Taron M, Ariza A, Barnadas A, Mate J, Reguart N . Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol. 2004; 31(1 Suppl 1):20-7. DOI: 10.1053/j.seminoncol.2003.12.011. View

15.

Evans E, Moggs J, Hwang J, Egly J, Wood R . Mechanism of open complex and dual incision formation by human nucleotide excision repair factors. EMBO J. 1997; 16(21):6559-73. PMC: 1170260. DOI: 10.1093/emboj/16.21.6559. View

16.

Kiyohara C, Yoshimasu K . Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci. 2007; 4(2):59-71. PMC: 1796947. DOI: 10.7150/ijms.4.59. View

17.

Chen J, Larochelle S, Li X, Suter B . Xpd/Ercc2 regulates CAK activity and mitotic progression. Nature. 2003; 424(6945):228-32. DOI: 10.1038/nature01746. View

18.

Evans T . Chemotherapy in advanced non-small cell lung cancer. Semin Respir Crit Care Med. 2005; 26(3):304-13. DOI: 10.1055/s-2005-871989. View

19.

Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V . DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer. 2009; 10(2):118-23. DOI: 10.3816/CLC.2009.n.015. View

20.

Olaussen K, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V . DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006; 355(10):983-91. DOI: 10.1056/NEJMoa060570. View